Merck antiviral trial shows promising impact on Covid recovery time
Molnupiravir, the antiviral pill developed by Merck to treat Covid-19, speeded up patients’ recovery but failed to reduce risks of hospitalisation and death, full results of an extensive UK clinical trial showed.
A peer-reviewed paper published in The Lancet confirmed preliminary findings released in October that molnupiravir — marketed by the US pharmaceutical group as Lagevrio — did not prevent the most severe disease among the 25,700 participants.
But researchers at Oxford university, who led the so-called Panoramic trial, put more emphasis on the positive secondary outcomes at a media briefing on Thursday.
This story originally appeared on: Financial Times - Author:Clive Cookson
